Methods for determining biodistribution of intravitreal administered medicaments
OwnerJohn Christoforidis, Michael Knoppinventors
Life of this patent
Estimating the term…
Abstract
Methods for determining systemic biodistribution characteristics of intravitrially administered medicaments. In some embodiments, radiolabeled agents or medicaments, such as I-124 labeled bevacizumab, ranibizumab and aflibercept, was imaged utilizing PET/CT in a non-human primate model, with radioactivity emission measurements made to determine the intravitreal half-lives of each agent and to determine the differences of radioactivity uptake in non-ocular organs.
Claims12
A method for determining a systemic biodistribution of a radiolabeled intravitreally-placed medicament in a subject, the method comprising the steps of:
- intraocularly placing a radiolabeled medicament including an anti-vascular endothelial growth factor (anti-VEGF) drug into the vitreous cavity of a subject's eye through the pars plana of the subject's eye;
- and
- with a digital PET/CT (dPET/CT) apparatus, performing positron emission tomography (PET) imaging of radioactive emission of bodily parts that include the subject's eye and one or more of bladder, liver, heart, spleen, renal organs, and femur bones covered by a field-of-view of said dPET/PC apparatus, to quantify an uptake of said medicament containing the anti-VEGF drug systemically by said bodily parts to identify systemic side effects of the uptake of said medicament following the intraocularly placing.
A method for determining a biodistribution of a radiolabeled medicament containing an anti-vascular endothelial growth factor (anti-VEGF) drug in a subject, the method comprising the step of:
- performing positron emission tomography (PET) imaging of radioactive emission of a subject's eye and one or more non-ocular organs within a field of view of a tomographer used for said imaging to identify systemic uptake of said anti-VGEF drug by the one or more non-ocular organs after intraocular placement of said radiolabeled medicament containing an anti-VEGF drug into the vitreous cavity of the subject's eye through the pars plana of the subject's eye.
Dependencies are inferred from the claim text.